CareRx Inkomsten in het verleden

Verleden criteriumcontroles 0/6

CareRx is de winst gegroeid met een gemiddeld jaarlijks percentage van 21.2%, terwijl de Consumer Retailing industrie de winst jaarlijks groeide met 6.5%. De inkomsten zijn gegroeid met een gemiddelde van 26% per jaar.

Belangrijke informatie

21.2%

Groei van de winst

51.0%

Groei van de winst per aandeel

Consumer Retailing Groei van de industrie	10.3%
Inkomstengroei	26.0%
Rendement op eigen vermogen	-8.8%
Nettomarge	-1.9%
Volgende winstupdate	08 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

Oct 03

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Aug 11

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Apr 22

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

Mar 17

Is CareRx Corporation's (TSE:CRRX) Shareholder Ownership Skewed Towards Insiders?

Mar 15

Trade Alert: The Chairman Emeritus Of CareRx Corporation (TSE:CRRX), Jack Shevel, Has Just Spent CA$850k Buying 9.4% More Shares

Feb 08

Reflecting on CareRx's (TSE:CRRX) Share Price Returns Over The Last Three Years

Dec 29

Opbrengsten en kosten

Hoe CareRx geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TSX:CRRX Opbrengsten, kosten en inkomsten (CAD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	367	-7	99
31 Mar 24	369	-4	98
31 Dec 23	371	-5	98
30 Sep 23	374	-6	100
30 Jun 23	378	-7	100
31 Mar 23	380	-34	101
31 Dec 22	382	-34	103
30 Sep 22	384	-34	101
30 Jun 22	358	-36	94
31 Mar 22	311	-20	83
31 Dec 21	263	-23	71
30 Sep 21	212	-21	61
30 Jun 21	187	-24	55
31 Mar 21	177	-29	52
31 Dec 20	162	-18	48
30 Sep 20	148	-50	44
30 Jun 20	134	-47	42
31 Mar 20	126	-34	41
31 Dec 19	125	-46	41
30 Sep 19	122	-19	42
30 Jun 19	119	-20	41
31 Mar 19	117	-39	41
31 Dec 18	119	-35	41
30 Sep 18	85	-27	27
30 Jun 18	97	-23	31
31 Mar 18	110	-3	34
31 Dec 17	122	-4	38
30 Sep 17	168	-6	55
30 Jun 17	170	-3	56
31 Mar 17	170	-13	58
31 Dec 16	167	-18	59
30 Sep 16	166	-21	64
30 Jun 16	166	-34	66
31 Mar 16	164	-30	67
31 Dec 15	161	-35	67
30 Sep 15	27	-47	13
30 Jun 15	60	-48	27
31 Mar 15	97	-49	41
31 Dec 14	135	-44	55
30 Sep 14	301	-48	120
30 Jun 14	295	-43	119
31 Mar 14	289	-49	119
31 Dec 13	281	-39	119

Kwaliteitswinsten: CRRX is momenteel verliesgevend.

Groeiende winstmarge: CRRX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CRRX is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 21.2% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CRRX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CRRX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Consumer Retailing industrie ( -11.7% ).

Rendement op eigen vermogen

Hoge ROE: CRRX heeft een negatief Return on Equity ( -8.76% ), omdat het momenteel verliesgevend is.

CareRx Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Insider selling

CareRx Corporation Announces Board Changes

Consensus EPS estimates increase by 386%

CareRx Corporation Announces CFO Transition

First quarter 2024 earnings: EPS exceeds analyst expectations

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

CareRx Corporation, Annual General Meeting, May 28, 2024

CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS misses analyst expectations

CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS exceeds analyst expectations

CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Carerx Corporation Announces Director Changes

First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022)

Consensus EPS estimates fall by 29%

Forecast breakeven date pushed back to 2025

Price target decreased by 11% to CA$5.23

Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021)

CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.

CareRx Corporation announced that it expects to receive CAD 8.0001 million in funding

CareRx Announces Retirement of Dr. Jack Shevel as Director Effective December 31, 2022

No longer forecast to breakeven

Price target decreased to CA$6.09

Less than half of directors are independent

Price target decreased to CA$6.15

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q3, 2022 Results on Nov 09, 2022

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

Consensus forecasts updated

Price target decreased to CA$6.93

Carerx Corporation Reports Goodwill and Intangible Assets Impairment Changes for the Three Months Ended June 30, 2022

CareRx Corporation to Report Q2, 2022 Results on Aug 15, 2022

President recently sold CA$230k worth of stock

CareRx Corporation (TSX:CRRX) completed the acquisition of Hogan Pharmacy Partners Ltd.

Consensus EPS estimates fall by 597%

Price target decreased to CA$8.52

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

Forecast breakeven date pushed back to 2024

CareRx Corporation to Report Q1, 2022 Results on May 11, 2022

Consensus forecasts updated

Less than half of directors are independent

CareRx Corporation Announces Executive Changes

CareRx Corporation, Annual General Meeting, Jun 07, 2022

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

Consensus forecasts updated

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Carerx Corporation Expands the Scope and Product Offering of Its Medical Supplies Business Under A New Brand, Revicare

Here's Why CareRx (TSE:CRRX) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of Long-Term Care Pharmacy Division of Medical Pharmacies Group Limited for CAD 72.9 million.

Consensus EPS estimates fall to -CA$0.72

Second quarter 2021 earnings released: CA$0.28 loss per share (vs CA$0.75 loss in 2Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of pharmacy fulfillment centre and portion of long-term care pharmacy services business of Rexall Pharma Plus Ltd.